Nasal Eosinophilic Inflammation Contributes to Bronchial Hyperresponsiveness in Patients with Allergic Rhinitis.
10.3346/jkms.2002.17.6.761
- Author:
An Soo JANG
1
Author Information
1. Department of Internal Medicine, Cheju National University College of Medicine, Jeju, Korea. jas877@cheju.ac.kr
- Publication Type:Original Article
- Keywords:
Rhinitis;
Allergic;
Eosinophils;
Bronchial Diseases;
Methacholine Chloride;
Asthma
- MeSH:
Adult;
Bronchi/*immunology;
Bronchial Hyperreactivity/*immunology;
Eosinophils/*immunology;
Female;
Humans;
Immunoglobulin E/blood;
Inflammation;
Male;
Rhinitis, Allergic, Perennial/*immunology;
Rhinitis, Allergic, Seasonal/*immunology;
Spirometry;
Time Factors
- From:Journal of Korean Medical Science
2002;17(6):761-764
- CountryRepublic of Korea
- Language:English
-
Abstract:
There are increasing evidences that allergic rhinitis (AR) may influence the clinical course of asthma. We conducted methacholine challenge test and nasal eosinophils on nasal smear to patients with allergic rhinitis in order to investigate the mechanism of connecting upper and lower airway inflammation in 35 patients with AR during exacerbation. The methacholine concentration causing a 20% fall in FEV1 (PC20) was used as thresholds of bronchial hyperresponsiveness (BHR). Thresholds of 25 mg/dL or less were assumed to indicate BHR. All patients had normal pulmonary function. Significant differences in BHR were detected in the comparison of patients with cough or postnasal drip and without cough or postnasal drip. There were significant differences of PC20 between patients with cough or postnasal drip and those without cough or postnasal drip (3.41 +/-3.59 mg/mL vs 10.2 +/-1.2 mg/mL, p=0.001). The levels of total IgE were higher in patients with seasonal AR than in patients with perennial AR with exacerbation (472.5 +/-132.5 IU/L vs. 389.0 +/-70.9 IU/L, p<0.05). Nasal eosinophils were closely related to log PC20 (r=-0.65, p<0.01). These findings demonstrated that nasal eosinophilic inflammation might contribute to BHR in patients with AR.
